Ildong gets exclusive right for paclitaxel PM technology

Published: 2007-11-15 06:56:00

Updated: 2007-11-15 06:56:00

Ildong Pharm has recently obtained an exclusive license for developing paclitaxel PM product and its delivery system in a strategic partnership with a Chinese company that received a Chinese patent in January of this year.

Paclitaxel PM is an innovative new formulation of the widely used anti-cancer drug, paclitaxel.

Ildong will begin Paclitaxel PM Phase I clinical trials in patients with...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.